TODAY.AZ / World news

Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children

23 October 2021 [11:57] - TODAY.AZ

By Trend

The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the U.S. drugmaker said on Friday, Trend reports citing Reuters.

Sixteen children in the trial who had received a placebo got COVID-19, compared with 3 who were vaccinated, Pfizer said in briefing documents submitted to the U.S. Food and Drug Administration.

Because more than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy.

Pfizer's clinical trial in those 5 to 11 years old was not primarily designed to measure efficacy against the virus. Instead, it compared the amount of neutralizing antibodies induced by the vaccine in the children to the response of older recipients in their adult trial.

 

Based on those results, Pfizer and BioNTech said last month that their COVID-19 vaccine induced a robust immune response in the children.

The 5 to 11 year olds were given two shots of a 10-microgram dose of the vaccine, a third of the dose size given to people 12 and older.

URL: http://www.today.az/news/regions/211280.html

Print version

Views: 454

Connect with us. Get latest news and updates.

Recommend news to friend

  • Your name:
  • Your e-mail:
  • Friend's name:
  • Friend's e-mail: